Protalix Says Reviewing Partnering, Other Alternatives
Protalix BioTherapeutics, Inc. (NYSE: PLX) confirms, in response to inquiries received this morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative.
Protalix will not comment further on this initiative unless future events would make doing so appropriate.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.